Revenue has shown wide variability with notable peaks in early 2025 and declines thereafter. The transition from substantial net income in 2025 to net losses in 2026 signals operational and market challenges. Operating expenses remain elevated due to consistent high R&D spending, impacting profitability.

Revenue peaked at over $1.1 billion in 2025, primarily driven by vaccine sales, but shrank to around $57 million in Q2 2026. This large fluctuation highlights dependence on product demand cycles and possibly supply chain or regulatory impacts. Gross margins remained strong when revenue was high, reflecting pricing power and cost efficiency in production.

Gross profit margins were exceptionally high, exceeding 70% during peak sales periods, illustrating strong cost control on core revenue activities. However, margins deteriorated substantially in recent quarters due to reduced revenue and persistent high R&D and operating expenses. EBITDA has swung from a strong positive to negative, reflecting unstable earnings capacity.

Earnings quality is challenged by fluctuating operating income and significant swings in net income consistency. The variability suggests episodic revenue streams and ongoing investment-related expenses which complicate stable profitability. Interest expenses and other net income items also affect bottom-line volatility.

Year-over-year revenue growth was robust in 2025, with revenue nearly doubling from 2024 levels. However, first half 2026 revenues declined drastically, with Q2 2026 revenue dropping approximately 60% sequentially from Q1. This marks a pronounced deceleration and contraction in core sales.

Earnings depicted a striking volatility pattern, turning from a $440 million net income in 2025 to negative $53 million in Q2 2026. EPS correspondingly shifted from positive $2.72 in 2025 to negative $0.32 most recently, indicating deteriorating profitability.

Growth has been driven mainly by the launch and sales volume of vaccine products, supported by ongoing innovation in R&D pipelines. Strong demand in 2025 related to pandemic and infectious disease vaccines played a key role. However, waning pandemic-related sales and market saturation are restricting growth now.

Growth has been largely organic from ramped vaccine sales but is inconsistent and subject to external demand shocks, making sustainability uncertain. Heavy reliance on a few key products underlines concentration risk in growth quality.

Gross margins peaked above 90% in strong sales quarters of 2025, showcasing operational leverage. Operating and net margins, however, fluctuated deeply from positive territory in 2025 to sharply negative levels in 2026, reflecting disproportionate expense structure relative to revenue.

Profitability metrics such as ROE and ROA are currently depressed due to net losses reported in 2026. In prior periods, returns were temporarily strong driven by sizable net income but are not sustained due to volatility in financial results and high expenses.

Given the volatility in sales and continued high R&D spending, margins are unlikely to sustain peak levels without consistent sales growth or operational scaling. Margin pressure is expected to persist without new product breakthroughs or expanded market uptake.